Loading SYNGENE price...
Peers are the listed companies in the exchange's own industry group: Healthcare Research Analytics & Technology. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 29 Jul 2026), sales fell 15.8% from a year earlier to Rs 736 cr and profit turned to a loss of Rs 9.0 cr from Rs 86.7 cr a year earlier.
- Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
- Profit fell 2 years running (Rs 510 cr in FY24 to Rs 317 cr in FY26).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 20 results, the share rose on 8 and fell on 12, and moved by 3% or more on 13.
Q1 FY27: results filed 29 Jul 2026. The share went from its close on 28 Jul 2026 to its close on 30 Jul 2026 -2.43%.
Majority owned by Biocon but separately listed on the NSE with its own public shareholders, Syngene does not sell any drugs of its own. It is a contract research, development and manufacturing organisation, running outsourced discovery labs and manufacturing plants on behalf of global pharmaceutical, biotech, agrochemical, animal health and nutrition companies, several of whom operate dedicated research centres inside Syngene's own facilities.
Pharma - CRO/CDMO
Contract R&D and manufacturing services spanning drug discovery, pre-clinical and clinical development, and commercial-scale manufacturing of small molecules and biologics, plus dedicated research capacity built for specific clients.
Large global pharmaceutical and biotech firms, including strategic partners such as Bristol-Myers Squibb, Baxter and Amgen, along with agrochemical, nutrition and animal health companies that outsource R&D and manufacturing rather than building it in-house.
Earns fees for scientific and manufacturing work performed for clients, either per project or through long-term dedicated-capacity contracts where a client funds part of a Syngene facility. Revenue depends on client R&D budgets and how many large multi-year contracts it holds.
Of every Rs 100 of sales in FY26, Rs 75 went on running costs, Rs 12 on depreciation, Rs 1.3 on interest and Rs 2.5 on tax; Rs 8.5 was left as profit.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales growthSales against the previous financial year. | - | - | - | 4.4% | 2.6% |
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | 30.6% | - | 29.1% | 28.6% | 24.6% |
| Net marginProfit after everything, per Rs 100 of sales. | 15.2% | - | 14.6% | 13.6% | 8.5% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | - | 12.0% | 10.5% | 6.5% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | - | 13.8% | 13.3% | 13.2% | 8.3% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | - | 0.16x | 0.03x | 0.03x | 0.00x |
| Interest coverHow many times operating profit covers the interest bill. Higher is safer. | 21.1x | - | 14.2x | 13.4x | 9.4x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 7,055 Cr of assets. Its owners funded 69% of that and borrowings 0%.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs 915 Cr, spent Rs 344 Cr on plant and equipment, and cash fell by Rs 139 Cr over the year.
Rs 100 or more means every rupee of reported profit arrived as cash.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP Apollo Hospitals Enterprise Limited | 1.13 L cr | 54.0x | 11.9x | 21.8% | 19.5% | 0.57 | 8.2% | +20.6% | 0.26% |
| MAXHEALTH Max Healthcare Institute Limited | 81,266 cr | 56.0x | 7.6x | 13.6% | 12.7% | 0.32 | 16.7% | +16.7% | 0.18% |
| MANIPALHOS Manipal Health Enterprises Limited | 73,581 cr | - | - | - | - | - | - | - | - |
| FORTIS Fortis Healthcare Limited | 55,467 cr | 52.9x | 5.6x | 10.5% | 12.0% | 0.28 | 11.3% | +17.5% | 0.14% |
| NH Narayana Hrudayalaya Ltd. | 33,971 cr | 41.4x | 7.5x | 18.0% | 11.4% | 1.07 | 9.0% | +78.0% | 0.27% |
| ASTERDM Aster DM Quality Care Limited | 33,523 cr | 104.9x | 7.3x | 7.5% | 10.2% | 0.15 | 7.4% | +21.6% | 0.16% |
| MEDANTA Global Health Limited | 32,575 cr | 58.6x | 8.2x | 13.9% | 15.1% | 0.30 | 11.8% | +26.5% | 0.04% |
| LALPATHLAB Dr. Lal Path Labs Ltd. | 31,100 cr | 44.8x | 12.4x | 21.5% | 25.7% | 0.00 | 18.9% | +19.1% | 0.72% |
| KIMS Krishna Institute of Medical Sciences Limited | 28,123 cr | 131.3x | 12.5x | 7.6% | 8.2% | 1.27 | 4.6% | +35.3% | 0.74% |
| AGARWALEYE Dr. Agarwal's Health Care Limited | 15,065 cr | 102.2x | 7.4x | 8.7% | 9.7% | 0.07 | 8.4% | +26.0% | 0.01% |
| SYNGENE Syngene International Limited | 14,527 cr | 65.5x | 3.0x | 4.6% | 8.3% | 0.00 | 6.1% | -15.8% | 0.35% |
| INDGN Indegene Limited | 14,472 cr | 36.3x | 4.6x | 12.8% | 15.4% | 0.00 | 10.5% | +39.7% | 0.33% |
| VIJAYA Vijaya Diagnostic Centre Limited | 14,362 cr | 76.7x | 15.0x | 19.6% | 19.2% | 0.00 | 21.9% | +22.8% | 0.14% |
| RAINBOW Rainbow Childrens Medicare Limited | 11,802 cr | 41.3x | 7.2x | 17.4% | 16.8% | 0.00 | 15.9% | +33.2% | 0.26% |
| METROPOLIS Metropolis Healthcare Limited | 10,989 cr | 22.8x | 7.3x | 13.3% | 15.7% | 0.01 | 11.9% | +16.6% | 0.19% |
| PARKHOSPS Park Medi World Limited | 9,487 cr | - | 4.7x | - | 18.1% | 0.11 | - | - | 0.00% |
| YATHARTH Yatharth Hospital & Trauma Care Services Limited | 8,924 cr | 49.3x | 4.9x | 9.7% | 11.0% | 0.14 | 13.1% | +52.3% | 0.00% |
| HCG Healthcare Global Enterprises Limited | 8,508 cr | 367.6x | 6.4x | 2.4% | 6.9% | 0.65 | 1.3% | +13.4% | 0.00% |
| THYROCARE Thyrocare Technologies Limited | 7,491 cr | 27.6x | 12.8x | 30.0% | 33.6% | 0.00 | 20.1% | +24.3% | 1.98% |
| SUVEN Suven Life Sciences Limited | 6,917 cr | - | 11.7x | - | -46.5% | 0.00 | - | +91.0% | 0.00% |
| NEPHROPLUS Nephrocare Health Services Limited | 6,095 cr | - | 5.5x | - | 13.7% | 0.07 | - | - | 0.00% |
| ARTEMISMED Artemis Medicare Services Limited | 4,547 cr | 40.0x | 4.9x | 12.1% | 13.7% | 0.24 | 10.2% | +12.7% | 0.13% |
| INDRAMEDCO Indraprastha Medical Corporation Limited | 2,750 cr | 20.8x | 3.7x | 25.4% | 30.7% | 0.00 | 12.3% | +11.3% | 1.49% |
| VIMTALABS Vimta Labs Limited | 2,185 cr | 27.7x | 4.8x | 17.4% | 21.2% | 0.01 | 19.0% | +11.8% | 0.20% |
| JLHL Jupiter Life Line Hospitals Limited | 1,658 cr | 8.8x | 1.1x | 12.1% | 13.8% | 0.33 | 12.0% | +18.2% | 0.40% |
| SURAKSHA Suraksha Diagnostic Limited | 1,628 cr | 45.4x | 6.7x | 14.4% | 14.7% | 0.01 | 10.8% | +20.8% | 0.00% |
| KRSNAA Krsnaa Diagnostics Limited | 1,617 cr | 16.8x | 1.6x | 9.9% | 10.6% | 0.55 | 11.9% | +22.1% | 0.55% |
| GKSL Gujarat Kidney And Super Speciality Limited | 1,400 cr | 70.8x | 5.5x | 6.6% | 8.6% | 0.06 | 16.6% | - | 0.00% |
| SHALBY Shalby Limited | 1,240 cr | 32.9x | 1.2x | 3.7% | 7.9% | 0.54 | 3.2% | +11.7% | 0.00% |
| GPTHEALTH GPT Healthcare Limited | 1,066 cr | 22.6x | 4.0x | 17.6% | 16.4% | 0.06 | 9.6% | +17.8% | 1.92% |
| HEALTHX Health X Platform Limited | 857 cr | - | 1.3x | -3.4% | - | - | -1.8% | +49.7% | 0.00% |
| GAUDIUMIVF Gaudium IVF and Women Health Limited | 674 cr | - | 4.4x | - | 23.1% | 0.15 | - | - | 0.00% |
| LOTUSEYE Lotus Eye Hospital and Institute Limited | 236 cr | 1419.5x | 3.9x | 0.2% | 1.1% | 0.19 | 0.3% | +26.2% | 0.00% |
| TAKE TAKE Limited | 154 cr | - | 5.0x | - | 15.4% | 0.00 | - | - | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from 30.6% to 24.6% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2026 has paid Rs 1.25 per share, about Rs 347 on Rs 1 lakh at today's price. It skipped 3 of the last 10 years. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.